BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.
See affected DINs and lot numbers on Health Canada ↗Why it was recalled
New safety information - Product safety
Other Recent Recalls
PDP-DIPHENHYDRAMINE
PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)
Type II2026-11-09
Moderate health risk
Unauthorized injectable peptide and non-peptide drugs
Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs
2026-11-06
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks
2026-11-03
Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.